{"id":"NCT01857583","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","officialTitle":"Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2013-05-20","resultsPosted":"2015-01-26","lastUpdate":"2019-03-05"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"15mg DU-176b","otherNames":["edoxaban"]},{"type":"DRUG","name":"30mg DU-176b","otherNames":["edoxaban"]},{"type":"DRUG","name":"Fondaparinux","otherNames":[]}],"arms":[{"label":"SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)","type":"EXPERIMENTAL"},{"label":"MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)","type":"EXPERIMENTAL"},{"label":"Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)","type":"ACTIVE_COMPARATOR"},{"label":"SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)","type":"EXPERIMENTAL"}],"summary":"To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of the lower limbs.\n\nFor reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of the lower limbs will be compared with that of fondaparinux.","primaryOutcome":{"measure":"Incidence of Any Adjudicated Bleeding Events","timeFrame":"14 days","effectByArm":[{"arm":"MiRI 30mg DU 176b (50 mL/Min ≤ CLCR ≤ 80 mL/Min)","deltaMin":33.3,"sd":null},{"arm":"SRI 15mg DU 176b (15 mL/Min ≤ CLCR < 20 mL/Min)","deltaMin":14.3,"sd":null},{"arm":"SRI 15mg DU 176b (20 mL/Min ≤ CLCR < 30 mL/Min)","deltaMin":22.7,"sd":null},{"arm":"Fondaparinux (20 mL/Min ≤ CLCR < 30mL/Min)","deltaMin":40,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["25653574"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Gamma-glutamyltransferase increased","Haemorrhage subcutaneous","cystitis","Blood urine present","Aspartate aminotransferase increased"]}}